Principal Investigator/Program Director (Last, First, Middle):
London, Edythe D.
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
London, Edythe D.
Professor of Psychiatry & Biobehavioral Sciences
Professor of Molecular & Medical Pharmacology
eRA COMMONS USER NAME
London2
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
DEGREE
(if applicable)
YEAR(s)
FIELD OF STUDY
George Washington University, Washington, DC
B.S.
1969
Zoology
Towson University, Towson, MD
M.S.
1973
Biology
University of Maryland, Baltimore, MD
Ph.D.
1976
Pharmacology
John Hopkins School of Medicine, Baltimore, MD Postdoctoral
1978
Psychopharmacology
A. Positions and Honors
Positions and Employment
10/76-12/78 NIMH postdoctoral fellow in Div. Psychopharmacology, Johns Hopkins School of Medicine
01/79-09/82 Gerontology Research Center, National Institute on Aging
09/82-07/99 Chief, Neuropharmacology Section, Intramural Research Program, NIDA
09/93-07/99 Director, Brain Imaging Center, Intramural Research Program, NIDA
Associate Professor, Div. Nuclear Medicine, Johns Hopkins School of Medicine
Adjunct Professor, Dept. Pharmacology & Experimental Ther., Univ. Maryland Sch. Med.
07/99-09/01 Visiting Professor, Dept. Psychiatry and Biobehavioral Sciences, Neuropsychiatric Inst., UCLA
10/01Professor, Depts. Psychiatry & Pharmacology, David Geffen School of Medicine, UCLA
Honors
1987
Mathilde Solowey Lecture Award in the Neurosciences
1988
ADAMHA Administrator's Award for Equal Employment Opportunity Achievement
07/90
NIDA Director's Award: Public education about NIDA’s program on drug effects on the brain
10/98
NIDA Director’s Merit Award: Developing a Radiotracer for Nicotinic Acetylcholine Receptors
B. Selected Peer-reviewed publications (in chronological order from a total of 241)
1. London E, Broussolle EPM, Links JM, Wong DF, et al. Morphine-induced metabolic changes in human
brain: Studies with positron emission tomography and [18F]fluorodeoxyglucose. Arch Gen Psychiatry
1990;47:73-81.
2. London E, Cascella N, Wong D, Phillips R, et al. Cocaine-induced reduction of glucose utilization in
human brain. A study using positron emission tomography and [18F]fluorodeoxyglucose. Arch Gen
Psychiatry 1990;47:567-574.
3. Phillips RL, Chen CY, Wong DF, London E. An improved method to calculate metabolic rates for
glucose using PET. J Nucl Med 1995;36:1668-1679.
4. Stapleton J, Morgan M, Phillips RL, Wong DF, Yung B, Shaya E, Dannals R, Liu X, Grayson R, London
E. Cerebral glucose utilization in polysubstance abuse. Neuropsychopharm. 1995;13:21-31.
5. Grant S, London E, Newlin DB, et al. Activation of memory circuits during cue-elicited cocaine craving.
Proc Natl Acad Sci USA 1996;93:12040-12045.
6. Stapleton J, Morgan M, Liu X, Yung B, Phillips RL, Wong DF, Shaya E, Dannals R, London E. Cerebral
glucose utilization is reduced in second test session. J Cereb Blood Flow Metab 1997;17:704-712.
7. Liu X, Matochik JA, Cadet JL, London E. Smaller volume of prefrontal lobe in polysubstance abusers: A
magnetic resonance imaging study. Neuropsychopharm. 1998;18:243-252.
8. Liu X, Vaupel DB, Grant S, London E. Effect of cocaine-related environmental stimuli on the
spontaneous electroencephalogram in polydrug abusers. Neuropsychopharm. 1998;19:10-17.
9. Bolla K, Cadet JL, London E. The neuropsychiatry of chronic cocaine abuse. J Neuropsychiat Clin
Neurosci 1998;10:280-289.
10. Horti A, Koren A, Lee K, Mukhin A, Vaupel D, Kimes A, Stratton M, London E. Radiosynthesis and
preliminary evaluation of 5-[123/125I]-Iodo-3-(2(S)-azetidinylmethoxy)-pyridine: A radioligand for nicotinic
Page 26
Principal Investigator/Program Director (Last, First, Middle):
London, Edythe D.
acetylcholine receptors. Nucl Med Biol 1999;26:175-182.
11. Morris ED, Chefer SI, Lane MA, Muzic Jr. RF, Wong D, Dannals R, Matochik J, Bonab A, Villemagne V,
Grant S, Ingram D, Roth GS, London E. Loss of D2 receptor binding with age in rhesus monkeys:
Importance of correction for differences in striatal size. J Cereb Blood Flow Metab 1999;19:218-29.
12. Bartzokis G, Lu PH, Beckson M, Rapoport R, Grant S, Wiseman EJ, London E. Abstinence from
cocaine reduces high-risk responses on a gambling task. Neuropsychopharm. 2000;22:102-103.
13. Grant S, Contoreggi C, London E. Drug abusers show impaired performance in a laboratory test of
decision making. Neuropsychologia 2000;38:1180-1187.
14. Mukhin AG, Gündisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, Chambers J, Vaupel DB, King
SI, Picciotto MR, Innis RB, London E. 5-Iodo-A-85380, an 42 subtype-selective ligand for nicotinic
acetylcholine receptors. Mol Pharmacol 2000;57:642-649.
15. Ernst M, Matochik J, Heishman S, Van Horn J, Jons P, Henningfield J, London E. Acute and chronic
nicotine effects on brain activation during performance of a working memory task. Proc Natl Acad Sci
USA 2001;98:4728-4733.
16. Ernst M, Heishman SJ, Spurgeon L, London E. Smoking history and nicotine effects on cognitive
performance. Neuropsychopharm. 2001;25:313-319.
17. Mintzer MZ, Griffiths RR, Contoreggi C, Kimes AS, London E, Ernst M. Effects of triazolam on brain
activity during episodic memory encoding: a PET study. Neuropsychopharm. 2001;25:744-756.
18. Ernst M, Bolla K, Mouratidis M, Contoreggi C, Matochik J, Kurian V, Cadet JL, Kimes AS, London E.
Decision-making in a risk-taking task: A PET study. Neuropsychopharmacology 2002;26:682-691.
19. Bonson KR, Grant SJ, Contoreggi CS, Links JM, Metcalfe J, Weyl HL, Kurian V, Ernst M, London E.
Neural systems and cue-induced cocaine craving. Neuropsychopharm. 2002;26:376-386.
20. Brody A, Mandelkern M, London E, et al. Brain metabolic changes during cigarette craving. Arch Gen
Psychiatry 2002;59:1162-1172.
21. Rose J, Behm F, Westman E, Mathew R, London E, Hawk T, Turkington TG, Coleman RE. Nicotinic
influences on neural systems: PET studies in cigarette smokers. Am J Psychiatry 2003;60:323-333.
22. Bolla KI, Eldreth DA, London E et al. Orbitofrontal cortex dysfunction in abstinent cocaine abusers
performing a decision-making task: NeuroImage 2003;19:1085-1094.
23. Kimes AS, Horti AG, London E et al. 2-[18F]F-A-85380: PET imaging brain nicotinic acetylcholine
receptors and whole body distribution in humans: FASEB J 2003;10:1331-1333.
24. Matochik JA, London E, Eldreth DA, Cadet J-L, Bolla KI. Frontal cortical tissue composition in abstinent
cocaine abusers: a magnetic resonance imaging study. NeuroImage 2003;19: 1095-1102.
25. Ernst M, Kimes AS, London E et al. Neural substrates of decision-making in attention-deficit
hyperactivity disorder. Am J Psychiatry 2003;160:1061-1070.
26. London E, Simon S, Berman S et al. Regional cerebral dysfunction associated with mood disturbances
in abstinent methamphetamine abusers. Arch Gen Psychiatry 2004;61:73-84.
27. Brody A, Mandelkern M, Jarvik M, Lee G, Smith E, Huang J, Bota R, Bartzokis G, London E:
Differences between smokers & non-smokers in regional gray matter volumes & densities. Biol Psychi.
2004;55:77-84.
28. Bolla K, Ernst M, Kiehl K, Mouratidis M, Eldreth D, Contoreggi C, Matochik J, Kurian V, Cadet J, Kimes
A, Funderburk F, London E. Prefrontal cortical dysfunction in abstinent cocaine abusers. Neuropsych
Clin Neurosci 2004;16:456-464.
29. Brody A, Olmstead R, London E, Farahi J, Meyer J, Grossman P, Lee G, Huang J, Hahn E,
Mandelkern, M: Smoking-induced ventral striatal dopamine release. Am J Psychiatry 2004;161: 12111218.
30. Brody A, Mandelkern M, Lee G, Smith E, Sadeghi M, Saxena S, Jarvik M, London E. Attenuated cueinduced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a
preliminary study. Psych Res Neuroimaging 2004;130:269-281.
31. Thompson P, Hayashi K, Simon S, Geaga J, Hong M, Sui Y, Lee J, Toga A, Ling W, London E.
Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci
2004;24: 6028-6036.
32. Monterosso JR, Aron AR, Cordova XI, Xu J, London E. Impaired response inhibition associated with
chronic methamphetamine abuse. Drug Alcohol Depend 2005;79:273-277.
33. Xu J, Mendrek A, Cohen MS, Monterosso J, Rodriquez P, Simon SL, Brody A, Jarvik M, Domier CP,
Olmstead R, Ernst M, London E. Brain activity in cigarette smokers performing a working memory task:
Page
Principal Investigator/Program Director (Last, First, Middle):
London, Edythe D.
Effects of smoking. Biol Psychiatry 2005;58:143-150.
34. Voytek B, Berman S, Hassid B, Simon S, Mandelkern M, Brody A, Monterosso J, Ling W, London E.
Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers.
Synapse 2004;57:113-115.
35. London E, Berman SM, Voytek BT, Simon SL, Monterosso, et al. Cerebral metabolic dysfunction and
impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry 2005;58:770-778.
36. Fishbein D, Eldreth D, Hyde C, Matochik JA, London E et al. Risky decision-making and the anterior
cingulate cortex in abstinent drug abusers and nonusers. Cogn Brain Res 2005;23:119-136.
37. Brody A, Mandelkern MA, London E, Olmstead RE, Farahi J, et al. Cigarette smoking saturates brain
α4β2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006;63:907-914.
38. Brody A, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S, Zamora-Paja E, Farahi J,
Saxena S, London E, McCracken JT. Gene variants of the brain dopamine reward pathway determine
smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry
2006;63:801-816.
39. Mendrek A, Monterosso JR, Simon SL, Jarvik M, Brody AL, Olmstead R, Domier CP, Cohen MS, Ernst
M, London ED. Working memory in cigarette smokers: comparison to non-smokers and effects of
abstinence. Addict Behav 2006; 31: 833-844.
40. Prosser J, Cohen LJ, Steinfeld M, Eisenberg DP, London ED, Galynker Il. Neuropsychological
functioning in opiate dependent subjects receiving and following methadone maintenance treatment.
Drug Alcohol Depend (in press 2006).
41. Monterosso JR, Domier CP, Ainslie G, Xu J, Cordova X, London ED. Frontoparietal cortical activity of
methamphetamine-dependent and comparison subjects performing a parametric delay-discounting task.
Hum Brain Mapp (in press 2006).
C. Research Support
Ongoing Research Support
R01DA020726 London (PI)
10/01/05-9/30/09
NIH/National Institute on Drug Abuse
Neural Systems, Inhibitory Control and Methamphetamine Dependence
This project measures response inhibition, and functional and structural integrity of brain regions thought to
mediate response inhibition in methamphetamine-dependent and healthy control subjects. It pairs functional
magnetic resonance imaging (fMRI) with tests of inhibitory control in research subjects receiving placebo
and modafinil. MRI is used to test hypotheses regarding gray matter volume in cortical and striatal regions.
Role: Principal Investigator
RO1 DA 15179 London (PI)
07/01/03-06/30/07
NIH/National Institute on Drug Abuse
Early Methamphetamine Abstinence: fMRI and Cognition
The goal of this project is to use functional magnetic resonance imaging (fMRI) to delineate the
abnormalities in the brain circuits that underlie cognitive deficits in methamphetamine abusers.
Role: Principal Investigator
RO3 DA202598 Lee (PI)
09/30/05-08/31/06
NIH/National Institute on Drug Abuse
Vervet Monkey Model for Methamphetamine-Induced Deficits in Response Inhibition
This project investigates the capacity for response inhibition in monkeys treated with methamphetamine on a
dosing regimen designed to mimic the pattern of methamphetamine abuse in humans. Reversal learning is
tested before and after drug treatment. One goal is to determine availability of the dopamine transporter the
striatum before and after MA treatment by using positron emission tomography and [ 11C]WIN 35,428.
Role: Co-Investigator
RO3 DA020512 O’Neill (PI)
09/30/05-08/31/06
NIH/National Institute on Drug Abuse
1H MRSI/Response Inhibition/Methamphetamine Abusers
To goal of this research is to relate regional brain chemistry and structure to performance in tests of
response inhibition in methamphetamine abusers and matched control subjects who do not use illicit drugs
of abuse. Measures taken will include structural MRI, proton Magnetic Resonance Spectroscopic Imaging
Page
Principal Investigator/Program Director (Last, First, Middle):
London, Edythe D.
(1H MRSI), and Diffusion Tensor Imaging, and will allow us to assess the structural and metabolic integrity of
frontostriatal centers thought to mediate response inhibition and of neighboring white matter.
Role: Co-Investigator
P20-RR020750-01 Bilder (PI)
09/28/04-07/31/07
NIH/Trans-NIH Roadmap Initiative
Cognitive Phenotyping for Neuropsychiatric Therapeutics
This project establishes an exploratory "Center for Cognitive Phenomics", to systematically identify discrete
cognitive endophenotypes important for interdisciplinary research on neuropsychiatric illnesses and their
effective treatments.
Role: Co-Investigator
R24 AT002681 Mayer (PI)
09/15/04-09/14/09
NIH/NCCAM
Mind/Brain/Body Interactions in Stress-Related Disorders
The goal of this grant is to develop infrastructure to provide expertise and technologies for the study of mindbrain-body interactions. After the full build up of the cores, there will be a Pilot and Feasibility program with
annual awards. These projects will use resources from core facilities and expertise of the involved faculty. A
career development program is included along with developmental and public infrastructure components.
Role: Co-Investigator
R01 MH069433-01A1 Saxena (PI)
06/01/04-05/31/08
NIH/National Institute on Mental Health
Neurobiology of Obsessive-Compulsive Hoarding
Goals: The goals of this project are to identify and characterize abnormalities in cerebral glucose
metabolism, brain morphology, and neurocognitive function in patients with the Compulsive Hoarding
Syndrome, using positron emission tomography, magnetic resonance imaging, and neuropsychological
testing.
Role: Co-Investigator
Completed Research Support (Selected, completed lat 3 years)
10RT-0091 London (PI)
07/01/01-06/30/06
University of California, Tobacco-Related Disease Research Program
Nicotine Withdrawal, Smoking and Attention: An fMRI Study.
The goal of this project was to determine the effects of cigarette smoking on selective attention and related
brain activation, as related to abstinence from smoking.
Role: Principal Investigator
R01 DA14093-02 London (PI)
09/30/01-04/30/06
NIH/National Institute on Drug Abuse
Nicotine Withdrawal, Smoking and Cognition: An fMRI Study.
The major goal of this project is to determine the effects of smoking history and condition on brain function
performance of the N-Back and Stroop tasks. This project uses functional imaging by fMRI to understand
the changes in attention and working memory that have been detected in smokers as a function of
abstinence and satiety.
Role: Principal Investigator
DABT63-00-C-1003 London (PI)
06/16/00-06/16/06
U.S. Army/Office of National Drug Control Policy
PET Combined with Stereotactic Probes to Develop Therapeutic Interventions for Drug Abuse.
The goal of this project is to develop a microPET scanner to do brain imaging research on non-human
primates, which can be used to investigate issues related to addiction.
Role: Principal Investigator
Page